ANTIHYPERTENSIVE LABELING SHOULD INCLUDE DEMONSTRATED BENEFITS OF REDUCED STROKE INCIDENCE AND CORONARY EVENTS, FDA CARDIORENAL ADVISORY CMTE. AGREES

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".